Comparing 2-day vs 3-day flu-CY lymphodepleting regimens for CD19 CAR T-cell therapy in patients with non-hodgkin’s lymphoma

Comparing 2-day vs 3-day flu-CY lymphodepleting regimens for CD19 CAR T-cell therapy in patients with non-hodgkin’s lymphoma

IntroductionLymphodepleting chemotherapy (LDC) is critical to CAR T-cell expansion and efficacy. Despite this, there is not a consensus in the literature regarding the optimal LDC regimen, including dose and frequency.MethodsWe retrospectively reviewed consecutive patients at a single institution th...

Full description

Bibliographic Details
Main Authors: David G. Frame, Marcus Geer, Salena Kasha, Denise Markstrom, Gianni Scappaticci, Tate Feeney, Andrew Hayduk, Hilary M. Mansoor, Avery Oberfeld, Hannah D’Antonio, Sarah Anand, Sung Won Choi, John Maciejewski, Attaphol Pawarode, Mary Mansour Riwes, Muneesh Tewari, John Magenau, Monalisa Ghosh
Format: Article
Language:English
Published: Frontiers Media S.A. 2024-06-01
Series:Frontiers in Immunology
Subjects:
CAR T-cell
non-hodgkin’s lymphoma
lymphodepletion
CRS
ICANS
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2024.1403145/full

Internet

https://www.frontiersin.org/articles/10.3389/fimmu.2024.1403145/full

Similar Items